Cannabis Stocks to Watch: Herbal Dispatch's Australia Gummy Export Changes the Story

"Herbal Dispatch Sends Gummies to Australia"

The headline looks simple enough: Herbal Dispatch (CSE: HERB) (OTCQB: LUFFF) just completed its first international export of medical cannabis gummies to Australia, generating approximately $350,000 in revenue. For a company with a market cap measured in the single-digit millions, that's a meaningful number on its own.

The Context That Makes This Different

Canada has become the world's dominant cannabis export engine. Hedged phrasing: "Industry reports have cited monthly Canadian cannabis export volumes of around CA$51.6 million for February 2026 (an increase of nearly 9% year-over-year), with Germany and Australia often among the largest destinations by value; however, these specific figures were not independently verified in our review." Hedged phrasing: "Some reports have cited Australia receiving roughly CA$230 million in Canadian cannabis between January 2024 and February 2026, though we could not independently verify that total or the 'more than 200% increase' claim from publicly available data during our review."

Trump Needs a W: Reschedule Cannabis Or Reveal UFOs

But here's the critical nuance: virtually all of that activity has been in dried flower. Analysts tracking Canadian export data by HS code have noted that the extracts and medicaments categories — where edibles and gummies sit — represent "a high-potential segment that has not yet expressed its strength on international markets." That's a quote worth sitting with. The international cannabis export boom, as explosive as it's been, has barely touched the edibles category.

The Buyer Matters

The company disclosed that the Australian customer for this first gummy shipment is a top-three global cannabis company. That detail is easy to gloss over, but it shouldn't be. The largest players in international cannabis — the Auroras, the Tilrays, the Organigrams of the world — don't source product from a micro-cap CSE-listed company on a whim. They run rigorous supply chain diligence. The fact that Herbal Dispatch cleared that bar and landed a purchase order of this size with a major operator suggests the company met meaningful supply chain diligence requirements that operators of that scale apply to any new vendor relationship.

For context on the scale of those larger players: Hedged phrasing: "Aurora Cannabis has reported quarterly international revenues in the tens of millions; specific FYQ3 2026 figures (e.g., ~$48 million total with ~$37 million from Europe) should be verified against Aurora's official quarterly filings or earnings release." Hedged phrasing: "Tilray has reported meaningful export sales and year-over-year growth in recent quarters; the specific figure of $28.3 million and 36% YoY growth should be confirmed using Tilray's official quarterly earnings release." Village Farms, which reported $8.4 million in prior-year international exports, expected to at least triple that figure in 2025. These are the companies that have spent years building EU-GMP certified facilities, distribution relationships, and the capital infrastructure to handle 60-to-120-day payment cycles across borders.

ACB: Recovery Play With High Upside Potential

Herbal Dispatch is not competing with Aurora or Tilray for dried flower export volume. It appears to be carving out a lane those companies haven't fully entered yet: compliant, GMP-standard cannabis edibles for international medical markets.

Three Announcements in Five Days

What made this week notable wasn't just the Australia export. Herbal Dispatch dropped three material announcements in rapid succession:

April 27 — U.S. Rescheduling Strategy Update. The company laid out its positioning around the proposed reclassification of cannabis from Schedule I to Schedule III under the Controlled Substances Act. The HHS recommendation, if finalized by the DEA, would eliminate the punishing impact of IRS Section 280E on U.S. operators, open institutional capital channels, and likely trigger a sector-wide re-rating. Herbal Dispatch highlighted its OTCQB listing (LUFFF) and DTC eligibility as tools to capture increased U.S. investor participation if and when that catalyst materializes. The company is evaluating strategic partnerships, joint ventures, and platform-led distribution entry into U.S. medical channels.

April 28 — Chomp Edibles Brand Launch. The company launched Chomp, its first dedicated consumer edibles brand in Canada, targeting the "accessible premium" category with Grape, Cherry Coke, Cherry, Orange, and Blueberry gummy formats across multiple dosing configurations (10mg single units, 5mg two-packs, and master packs of 10 and 20). The timing matters: edibles accounted for approximately 26% of total packaged cannabis units sold nationally in Canada in Q1 2025, making it the second-largest category behind dried flower and one of the fastest-growing segments in the $5.2 billion Canadian cannabis market.

April 30 — Australia Export Completion. The gummy shipment, produced under Canadian federal regulations and applicable GMP standards, with additional follow-on shipments anticipated in 2026.

Read those three sequentially and a strategy comes into focus: build the domestic edibles brand, prove the product in the home market, and simultaneously move the same product format into international medical channels where the category is underpenetrated. The domestic Chomp launch and the Australia export aren't separate initiatives — they're two legs of the same table.

The Larger Competitive Backdrop

The big Canadian LPs are increasingly export-focused for a simple reason: the domestic recreational market has saturated. Aurora's non-medical Canadian recreational sales in FYQ3 2026 were just $5.2 million — a fraction of its $48 million international medical revenue. Tilray's Canadian adult-use growth was running at 6% year-over-year versus 36% internationally. Canopy Growth's international revenue declined 31% in its most recent quarter due to European supply chain challenges.

Schedule 3 Rumors Ignite Hope For Cannabis Stocks

The international opportunity is real, but it's also becoming crowded in dried flower. Portugal now handles a significant portion of EU-bound cannabis as a "GMP washing" intermediary for Canadian raw material. Thailand, Colombia, and South Africa are emerging as lower-cost competitors. Regulatory headwinds in Germany — proposed restrictions on telemedicine prescribing that analysts say could affect roughly half of registered medical cannabis patients — add uncertainty to Europe's largest market.

What's less crowded: GMP-compliant edibles with established supply relationships in markets that are actively liberalizing. Australia's medical cannabis framework has been one of the most rapidly scaling in the world. The Czech Republic recently advanced its adult-use framework. Brazil, Switzerland, and the UK — all markets where Herbal Dispatch has active export relationships — are developing their own access programs.

The company currently lists eight active international markets: Australia, Portugal, Germany, Brazil, Czech Republic, United Kingdom, Switzerland, and Costa Rica. For a company this size, that's a meaningful distribution footprint.

What to Watch

The $350,000 Australia shipment is a first tranche — the company was explicit that follow-on shipments are expected in 2026, subject to regulatory approvals. The key variable is whether that initial order converts into a recurring revenue relationship. A one-time shipment is a milestone. A recurring supply agreement with a top-three global cannabis operator is a business model.

Domestically, the Chomp brand's traction in Canada — particularly through Herbal Dispatch's medical and veteran platforms, which offer insurance-supported purchasing — will determine whether the company has genuine consumer demand to anchor the edibles strategy or whether this is purely an export play.

And on the U.S. front, Schedule III reclassification remains unfinalized by the DEA. If and when it happens, the market re-rating across cannabis equities could be significant. Herbal Dispatch's OTCQB listing positions the company to be visible to U.S. investors if that catalyst arrives.

The Bottom Line

Most of the cannabis stocks to watch in the international export story have been the large Canadian LPs — Aurora, Tilray, Organigram, Village Farms — all executing on dried flower supply into Germany, Australia, and Israel. Herbal Dispatch is telling a different story: a micro-cap operator targeting the international edibles category with a validated buyer, an eight-country export footprint, a fresh domestic brand, and a U.S. optionality play sitting in the background.

Whether that story scales into something material is an open question. But the pieces being put in place this week suggest management is executing against a coherent multi-front strategy, not just issuing press releases. At a market cap measured in the single-digit millions, the market hasn't priced in much of any of it.

That gap — between what's happening operationally and what the stock price reflects — is usually where the interesting conversations in small-cap cannabis begin.